IPHA Innate Pharma
- 2.384
- -0.156-6.15%
Innate Pharma News
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Innate Pharma's NK Cell Engager Enters Phase 2 Trials
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio
Express News | Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of Shareholders ("AGM") at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed
Express News | Innate Pharma Says It Filed Its 2023 Universal Registration Document (Document D'enregistrement Universel) And 2023 Annual Report On Form 20-F
Innate Pharma Files Its 2023 Universal Registration Document (Document D'enregistrement Universel) and 2023 Annual Report on Form 20-F
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2023 Universal Registration Docum
Innate Pharma's Growth at Risk: The Challenge of Relying on External Partners and a Lean Team
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersGalera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $12.3 million. As per the news, t
Innate Pharma SA: A Balanced Hold Rating Amidst Clinical Setbacks and Cautious Optimism
Analysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)
Express News | HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Innate Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 377.18% HC Wainwright & Co. → $11.5 Reiterates Buy → Buy 11/15/2023 377.18% HC Wainwright & Co.
Earnings Call Summary | Innate Pharma(IPHA.US) Q4 2023 Earnings Conference
The following is a summary of the Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript:Financial Performance:Innate Pharma reported cash, cash equivalents, short-term investments and financial a
Innate Pharma S.A.: Financial Overview and Gains
Analysis
Price Target
No Data
